Zobrazeno 1 - 10
of 18
pro vyhledávání: '"Charlotte Coles"'
Autor:
Andrew Poole, Vijaykumar Karuppiah, Annabelle Hartt, Jaafar N. Haidar, Sylvie Moureau, Tomasz Dobrzycki, Conor Hayes, Christopher Rowley, Jorge Dias, Stephen Harper, Keir Barnbrook, Miriam Hock, Charlotte Coles, Wei Yang, Milos Aleksic, Aimee Bence Lin, Ross Robinson, Joe D. Dukes, Nathaniel Liddy, Marc Van der Kamp, Gregory D. Plowman, Annelise Vuidepot, David K. Cole, Andrew D. Whale, Chandramouli Chillakuri
Publikováno v:
Nature Communications, Vol 13, Iss 1, Pp 1-15 (2022)
Cancers often harbor mutations in genes encoding important regulatory proteins, but therapeutic targeting of these molecules proves difficult due to their high structural similarity to their non-mutated counterpart. Here authors show the engineering
Externí odkaz:
https://doaj.org/article/d2f84672e7fe4eb3b7df368784cf9d36
Autor:
Iain Macpherson, Stuart McIntosh, Lucy Kilburn, Holly Tovey, Sarah Kernaghan, Katie Goddard, Indrani Bhattacharya, Clinton Boyd, Charlotte Coles, Cliona Kirwan, Mairead Mackenzie, Ciara O’Brien, Alistair Ring, Claire Snowdon, Hilary Stobart, Duncan Wheatley, Andrew Wardley, Abeer Shaaban, Peter Hall, David Cameron, Judith Bliss
Publikováno v:
Cancer Research. 82:OT2-05
Background The presence or absence of residual disease following neoadjuvant systemic anti-cancer therapy (neoSACT) for HER2-positive early breast cancer (HER2+ EBC) provides powerful prognostic information that may guide subsequent adjuvant treatmen
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2a21cd1f2ba7e31cfd59954e7383a662
https://doi.org/10.1158/1538-7445.sabcs21-ot2-05-01
https://doi.org/10.1158/1538-7445.sabcs21-ot2-05-01
Autor:
Mary Denholm, Henno Martin, Amit Roshan, Suzanne Miller, Glenn Harden, Sonakshi Kadyan, Catherine Towns, Paulius Mennea, Daniel Munoz-Espin, Charlie Massie, Nitzan Rosenfeld, Gillian Barnett, Robert Rintoul, Charlotte Coles, Huiqi Yang, Raj Jena
Publikováno v:
Lung Cancer. 178:S88
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::6cfe67c4679d28772387ede486dd232a
https://doi.org/10.1016/s0169-5002(23)00625-6
https://doi.org/10.1016/s0169-5002(23)00625-6
Autor:
Andrew, Poole, Vijaykumar, Karuppiah, Annabelle, Hartt, Jaafar N, Haidar, Sylvie, Moureau, Tomasz, Dobrzycki, Conor, Hayes, Christopher, Rowley, Jorge, Dias, Stephen, Harper, Keir, Barnbrook, Miriam, Hock, Charlotte, Coles, Wei, Yang, Milos, Aleksic, Aimee Bence, Lin, Ross, Robinson, Joe D, Dukes, Nathaniel, Liddy, Marc, Van der Kamp, Gregory D, Plowman, Annelise, Vuidepot, David K, Cole, Andrew D, Whale, Chandramouli, Chillakuri
Publikováno v:
Nature communications. 13(1)
Neoantigens derived from somatic mutations are specific to cancer cells and are ideal targets for cancer immunotherapy. KRAS is the most frequently mutated oncogene and drives the pathogenesis of several cancers. Here we show the identification and d
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::09b6f49fe5f2b3f9dd982b4e6d4e47e8
https://pubmed.ncbi.nlm.nih.gov/36088370
https://pubmed.ncbi.nlm.nih.gov/36088370
Autor:
Ian Whitehead, Gareth Irwin, Finian Bannon, Charlotte Coles, Ellen Copson, Ramsey Cutress, Rajiv Dave, Matthew Gardiner, Margaret Grayson, Chris Holcombe, Sheeba Irshad, Ciara O'Brien, Rachel O'Connell, Carlo Palmieri, Abeer Shaaban, Nisha Sharma, Jagdeep Singh, Shelley Potter, Stuart McIntosh
Background: Neoadjuvant systemic therapy (NST) is increasingly used in the treatment of breast cancer, yet it is clear that there is significant geographical variation in its use in the UK. This study aimed to examine stated practice across UK breast
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d762791bf932a6f6a60b3c0699e2a6c7
https://doi.org/10.21203/rs.3.rs-48473/v3
https://doi.org/10.21203/rs.3.rs-48473/v3
Autor:
Ian Whitehead, Gareth Irwin, Finian Bannon, Charlotte Coles, Ellen Copson, Ramsey Cutress, Rajiv Dave, Matthew Gardiner, Margaret Grayson, Chris Holcombe, Sheeba Irshad, Ciara O'Brien, Rachel O'Connell, Carlo Palmieri, Abeer Shaaban, Nisha Sharma, Jagdeep Singh, Shelley Potter, Stuart McIntosh
Background: Neoadjuvant systemic therapy (NST) is increasingly used in the treatment of breast cancer, yet it is clear that there is significant geographical variation in its use in the UK. This study aimed to examine stated practice across UK breast
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::822070c579c8f4849e428abad2d7fca5
https://doi.org/10.21203/rs.3.rs-48473/v1
https://doi.org/10.21203/rs.3.rs-48473/v1
Autor:
Adrian Murray Brunt, Joanne S Haviland, Duncan A Wheatley, Mark A Sydenham, Abdulla Alhasso, David J Bloomfield, Charlie Chan, Mark Churn, Susan Cleator, Charlotte E Coles, Andrew Goodman, Adrian Harnett, Penelope Hopwood, Anna M Kirby, Cliona C Kirwan, Carolyn Morris, Zohal Nabi, Elinor Sawyer, Navita Somaiah, Liba Stones, Isabel Syndikus, Judith M Bliss, John R Yarnold, Anne Armstrong, Judith Bliss, David Bloomfield, Jo Bowen, Murray Brunt, Hannah Chantler, Charlotte Coles, Ellen Donovan, Andy Goodman, Susan Griffin, Jo Haviland, Penny Hopwood, Anna Kirby, Julie Kirk, Cliona Kirwan, Marjory MacLennan, Mark Sculphur, Judith Sinclair, Mark Sydenham, Jean Tremlett, Karen Venables, Duncan Wheatley, John Yarnold
Publikováno v:
Lancet (London, England)
FAST-Forward Trial Management Group 2020, ' Hypofractionated breast radiotherapy for 1 week versus 3 weeks (FAST-Forward) : 5-year efficacy and late normal tissue effects results from a multicentre, non-inferiority, randomised, phase 3 trial ', Lancet (London, England), vol. 395, no. 10237, pp. 1613-1626 . https://doi.org/10.1016/S0140-6736(20)30932-6
FAST-Forward Trial Management Group 2020, ' Hypofractionated breast radiotherapy for 1 week versus 3 weeks (FAST-Forward) : 5-year efficacy and late normal tissue effects results from a multicentre, non-inferiority, randomised, phase 3 trial ', Lancet (London, England), vol. 395, no. 10237, pp. 1613-1626 . https://doi.org/10.1016/S0140-6736(20)30932-6
BACKGROUND: We aimed to identify a five-fraction schedule of adjuvant radiotherapy (radiation therapy) delivered in 1 week that is non-inferior in terms of local cancer control and is as safe as an international standard 15-fraction regimen after pri
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::53e395035946033bfb3c8db03e2d044a
Chapter 5 discusses breast radiotherapy and includes discussion on the evidence-based rationale for radiotherapy, including adjuvant loco-regional radiotherapy and other indications, adverse effects of breast and lymphatic radiotherapy, pre-planning
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::613e9eeca9c41dab25829c77d0e7869d
https://doi.org/10.1093/med/9780198786757.003.0005
https://doi.org/10.1093/med/9780198786757.003.0005
Publikováno v:
British Journal of Hospital Medicine. 77:204-207
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c0fd7062360c791293c7087bff74772b
https://doi.org/10.12968/hmed.2016.77.4.204
https://doi.org/10.12968/hmed.2016.77.4.204
Publikováno v:
Dermatologic Surgery. 31:375-378
Objective To evaluate a novel light patch formulated for blue light delivery and topical activation of γ-aminolevulinic acid (ALA) during photodynamic therapy for the treatment of actinic keratosis (AK). Materials and Methods Ten volunteers with pas
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::958c9c6f5174c1c36cffb9da9bb8dbb2
https://doi.org/10.1097/00042728-200503000-00025
https://doi.org/10.1097/00042728-200503000-00025